Related Experiment Video
Updated: Mar 19, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
A Broad-Spectrum Infection Diagnostic that Detects Pathogen-Associated Molecular Patterns (PAMPs) in Whole Blood
Mark Cartwright1, Martin Rottman2, Nathan I Shapiro3
1Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, United States.
Background:
Blood cultures, and molecular diagnostic tests that directly detect pathogen DNA in blood, fail to detect bloodstream infections in most infected patients. Thus, there is a need for a rapid test that can diagnose the presence of infection to triage patients, guide therapy, and decrease the incidence of sepsis.
Methods:
An Enzyme-Linked Lectin-Sorbent Assay (ELLecSA) that uses magnetic microbeads coated with an engineered version of the human opsonin, Mannose Binding Lectin, containing the Fc immunoglobulin domain linked to its carbohydrate recognition domain (FcMBL) was developed to quantify pathogen-associated molecular patterns (PAMPs) in whole blood. This assay was tested in rats and pigs to explore whether it can detect infections and monitor disease progression, and in prospectively enrolled, emergency room patients with suspected sepsis. These results were also compared with data obtained from non-infected patients with or without traumatic injuries.
Results:
The FcMBL ELLecSA was able to detect PAMPS present on, or released by, 85% of clinical isolates representing 47 of 55 different pathogen species, including the most common causes of sepsis. The PAMP assay rapidly (<1h) detected the presence of active infection in animals, even when blood cultures were negative and bacteriocidal antibiotics were administered. In patients with suspected sepsis, the FcMBL ELLecSA detected infection in 55 of 67 patients with high sensitivity (>81%), specificity (>89%), and diagnostic accuracy of 0·87. It also distinguished infection from trauma-related inflammation in the same patient cohorts with a higher specificity than the clinical sepsis biomarker, C-reactive Protein.
Conclusion:
The FcMBL ELLecSA-based PAMP assay offers a rapid, simple, sensitive and specific method for diagnosing infections, even when blood cultures are negative and antibiotic therapy has been initiated. It may help to triage patients with suspected systemic infections, and serve as a companion diagnostic to guide administration of emerging dialysis-like sepsis therapies.
Insights
A new Enzyme-Linked Lectin-Sorbent Assay (ELLecSA) rapidly detects pathogen-associated molecular patterns (PAMPs) in blood. This assay shows promise for diagnosing bloodstream infections, even when blood cultures are negative.
Area of Science:
- Infectious Disease Diagnostics
- Biomarker Discovery
- Immunology
Background:
- Current blood culture and molecular tests often fail to detect bloodstream infections.
- A rapid diagnostic test is needed to improve sepsis patient triage and therapy.
- Existing methods lack sensitivity and speed for timely infection diagnosis.
Purpose of the Study:
- To develop and evaluate a novel assay for rapid detection of pathogen-associated molecular patterns (PAMPs) in whole blood.
- To assess the diagnostic performance of the FcMBL ELLecSA in animal models and human patients with suspected sepsis.
- To compare the assay's specificity against trauma-related inflammation and C-reactive Protein.
Main Methods:
- Development of an Enzyme-Linked Lectin-Sorbent Assay (ELLecSA) using engineered Mannose Binding Lectin (FcMBL) on magnetic microbeads.
- Quantification of PAMPs in whole blood from infected rats and pigs, and prospectively enrolled emergency room patients.
- Comparison of FcMBL ELLecSA results with blood cultures, C-reactive Protein levels, and data from non-infected patients.
Main Results:
- The FcMBL ELLecSA detected PAMPs from 85% of clinical isolates across 47 species, including common sepsis pathogens.
- The assay provided rapid (<1h) detection of active infection in animals, outperforming blood cultures and antibiotic treatment.
- In patients, the FcMBL ELLecSA achieved >81% sensitivity, >89% specificity, and 0.87 accuracy for sepsis detection, distinguishing infection from trauma.
Conclusions:
- The FcMBL ELLecSA offers a rapid, sensitive, and specific method for diagnosing infections, even with negative blood cultures or ongoing antibiotic therapy.
- This PAMP assay can aid in triaging suspected systemic infections and guiding sepsis therapies.
- The assay demonstrates potential as a companion diagnostic for novel sepsis treatments.
More Related Videos
Related Concept Videos
Automated Microbial Diagnostics
Modern Molecular Taxonomy
Methods of Classification and Identification

